Precision radiotherapy, molecular MRI, brain cancer, Johns Hopkins

The National Library of Medicine registered clinical trial NCT07512154 on ClinicalTrials.gov. The trial, sponsored by Johns Hopkins University, studies precision radiotherapy combined with molecular MRI for brain cancer. This registration fulfills requirements under 42 U.S.C. §282 for federally funded clinical trials to be publicly registered.

AML clinical trial investigating TP53 mutation treatment

The National Library of Medicine registered a new clinical trial on ClinicalTrials.gov (NCT07511062) investigating treatment for TP53 mutations in Acute Myeloid Leukemia (AML) patients. This is an informational registry entry providing public access to trial information as required under federal clinical trial registration requirements.

Sacituzumab tirumotecan Phase 2 anal/rectal cancer trial

The National Library of Medicine registered a new Phase 2 clinical trial (NCT07511023) on ClinicalTrials.gov evaluating sacituzumab tirumotecan for the treatment of anal and rectal cancer. The single-arm study will enroll participants with metastatic or locally advanced disease. This trial registration provides public transparency on an ongoing cancer immunotherapy study.

AZD1043 Safety Study - AstraZeneca/Parexel

The National Library of Medicine updated ClinicalTrials.gov to add a new Phase 1 safety study for AZD1043 sponsored by AstraZeneca and Parexel. The trial is listed as 'not recruiting.' Clinical investigators and pharmaceutical sponsors should ensure their trials are properly registered.

VDBD Treatment Clinical Trial NCT07513129

The National Library of Medicine registered clinical trial NCT07513129 on ClinicalTrials.gov to study VDBD treatment. The trial is now publicly accessible in the clinical trials database.

Venetoclax CACAG versus 3+7 regimen acute monocytic leukemia

The National Library of Medicine registered a new Phase 2 clinical trial (NCT07512700) on ClinicalTrials.gov investigating venetoclax-based CACAG regimen versus standard 3+7 chemotherapy for acute monocytic leukemia in adult patients. The trial is currently recruiting participants.

Lawyer Niche Focus Builds Expertise, Value Over Price

The American Bar Association published an informational article advising lawyers on practice development strategy. The article argues that lawyers who narrow their practice focus develop deeper expertise, attract higher-value clients, and avoid price competition compared to generalists. The article includes two self-assessment tests for evaluating current positioning.

AI Impact on Law Practice - TECHSHOW 2026 Podcast Recap

The ABA Law Practice Division published a podcast recap from TECHSHOW 2026 featuring three attorneys discussing Jordan Furlong's keynote on AI's impact on legal practice. Panelists addressed AI capabilities resembling a third-year associate, emerging attorney-client privilege questions, debates on bar exam reform and law school relevance, and ethics concerns including hallucinated legal citations. The discussions encouraged lawyers to develop practical AI skills and adopt firm-wide AI policies.

Maria Anzures-Camarena Permanent Debarment - FDA Drug Applications

FDA issued a permanent debarment order for Maria Anzures-Camarena, prohibiting her from submitting or assisting in the preparation of drug applications to the agency. The debarment stems from her felony conviction related to drug application matters. All FDA-regulated drug product applications submitted by or on behalf of Ms. Anzures-Camarena are permanently barred.

Permanent Debarment Order - Miguel Angel Montalvo Villa

The FDA issued a Final Debarment Order permanently excluding Miguel Angel Montalvo Villa from submitting or providing assistance in the preparation of drug applications under section 306(a) or (b) of the FD&C Act. The debarment follows a conviction under federal law related to drug product approval. This action prohibits Montalvo Villa from any role in drug application submissions to FDA.